经会阴与经直肠入路磁共振成像靶向前列腺穿刺活检检测前列腺癌的比较:欧洲泌尿外科学会青年学术泌尿外科医师前列腺癌工作组多中心研究
这项多中心回顾性队列研究纳入10家转诊中心接受磁共振成像靶向前列腺穿刺活检的患者,比较经会阴与经直肠两种入路。经会阴组前列腺癌和临床显著前列腺癌检出率均高于经直肠组(64.0% vs 50%,p<0.01;49% vs 35%,p<0.01),多变量分析显示经会阴入路是两者的独立预测因素。
要点
- 经会阴靶向穿刺前列腺癌检出率64.0% vs 经直肠50%(p<0.01)。
- 经会阴靶向穿刺临床显著前列腺癌检出率49% vs 经直肠35%(p<0.01)。
- 经会阴入路独立预测前列腺癌(OR 1.37)和临床显著前列腺癌(OR 1.19)。
核心结论
- 经会阴磁共振成像靶向前列腺穿刺活检有助于更好地定义肿瘤分级和评估前列腺癌风险,对治疗决策和患者咨询有重要影响。
研究设计与样本
- 多中心回顾性队列研究,比较接受经会阴与经直肠磁共振成像靶向前列腺穿刺活检的患者。
- 共纳入10家转诊中心的1936例经直肠靶向穿刺患者和3305例经会阴靶向穿刺患者。
主要发现
- 经会阴组 vs 经直肠组前列腺癌检出率为64.0% vs 50%(p<0.01)。
- 经会阴组 vs 经直肠组临床显著前列腺癌(国际泌尿病理学会分级≥2)检出率为49% vs 35%(p<0.01)。
- 多变量分析校正年龄、初诊/重复活检、cT分期、前列腺影像报告和数据系统评分、前列腺体积、PSA及靶向穿刺针数后,经会阴入路是前列腺癌的独立预测因素(OR 1.37,95%CI 1.08-1.72)。
- 经会阴入路是临床显著前列腺癌的独立预测因素(OR 1.19,95%CI 1.12-1.50)。
- 按索引病灶部位分析,经会阴入路较经直肠入路检测临床显著前列腺癌的可能性在尖部(OR 4.81,95%CI 1.03-6.27)、移行/中央区(OR 2.67,95%CI 1.42-5.00)和前区(OR 5.62,95%CI 1.74-8.13)均更高。
临床怎么用
- 作者认为经会阴靶向穿刺活检有助于更好地定义肿瘤分级和评估前列腺癌风险,对治疗决策和患者咨询有重要影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our aim was to evaluate whether transperineal (TP) MRI-targeted prostate biopsy (TBx) may improve the detection of clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology ≥2, in comparison to transrectal (TR) TBx. MATERIALS AND METHODS: A multicenter retrospective cohort study comprising patients who underwent MRI-guided prostate biopsy was conducted. To address possible benefits of TP-TBx in the detection of prostate cancer (PCa) and csPCa, a cohort of patients undergoing TP-TBx were compared to patients undergoing TR-TBx. Multivariable logistic regression analyses were performed to assess predictors of PCa and csPCa detection. RESULTS: Overall, 1,936 and 3,305 patients who underwent TR-TBx vs TP-TBx at 10 referral centers were enrolled. The rate of PCa and csPCa diagnosed was higher for TP-TBx vs TR-TBx (64.0% vs 50%, p <0.01 and 49% vs 35%, p <0.01). At multivariable analysis adjusted for age, biopsy naïve/repeated biopsy, cT stage, Prostate Imaging-Reporting and Data System®, prostate volume, PSA, and number of biopsy cores targeted, TP-TBx was an independent predictor of PCa (odds ratio [OR] 1.37, 95% CI 1.08-1.72) and csPCa (1.19, 95% CI 1.12-1.50). When considering the approach according to the site of the index lesion, TP-TBx had a significantly higher likelihood than TR-TBx to detect csPCa in the apex (OR 4.81, 95% CI 1.03-6.27), transition/central zone (OR 2.67, 95% CI 1.42-5.00), and anterior zone (OR 5.62, 95% CI 1.74-8.13). CONCLUSIONS: The use of TP-TBx allows a better cancer grade definition and PCa risk assessment. This has important implication in the decision-making process and in patient counseling for further therapies.
引用
- Zattoni F, Marra G, Kasivisvanathan V, et al. The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. J Urol. 2022. PMID: 36082555. doi:10.1097/JU.0000000000002802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。